Skip to Content

Otolaryngology – Head and Neck Surgery Trials

Study of Human Airway Disease
Aims: This study is being conducted in support of Northwestern University (NU) investigator Dr. Robert Schleimer’s studies of Chronic Rhinosinusitis. Through sinus/nasal specimen collection and analysis we hope to better understand the causes of chronic sinus disease and to better understand how oral steroid treatment may affect the development of chronic sinusitis and polyps as well as their impact on surgical recovery.
Study Duration: 12 months
Diagnosis: Patient having Sinus/Nasal Surgery
IRB Approval Number: EH14-417
Sponsor: NorthShore University HealthSystem
Contact: For more information, interested participants and clinicians may contact Gnathan Carpenter at 847.570.2949 or email gcarpenter@northshore.org.
Open to Enrollment: Yes

Nucleus® Hybrid L24 Implant System: New Enrollment Study
Aims: The purpose of this study is to evaluate the long-term safety and effectiveness of the Nucleus Hybrid L24 cochlear implant system. The system consists of a Nucleus Hybrid L24 Cochlear Implant, a Sound Processor (a mini "computer" that amplifies sound and converts sound waves into an electric signal), and an Acoustic Component (AC), which consists of a mini speaker built into an earpiece that fits in your ear. The FDA has recently approved this system for marketing,
Study Duration: 5 years
Diagnosis: The Nucleus Hybrid Implant system is designed for patients who have severe hearing loss for high-pitched sounds but who have reasonably good hearing for lower pitched sounds, and who do not understand speech well with hearing aids alone.
IRB Approval Number: EH15-281
Sponsor: Cochlear Americas, Inc.
Contact: For more information, interested participants and clinicians may contact Mira Shiloach at 847.657.1750 or email mshiloach@northshore.org.
Open to Enrollment: Yes 

Randomized Controlled Trial of Vanglociclovir for Cytomegalovirus Infected Hearing Impaired Infants
Aims: The primary goal will be to determine whether cytomegalovirus (CMV) infected infants treated with the anti-viral drug, valganciclovir, for 6 months will have better hearing and language outcomes compared to those treated with placebo
Diagnosis: Patients that have been diagnosed with an infection called cytomegalovirus (CMV) and have hearing loss in one or both ears.
Principal Investigator: Mark Gerber, MD
IRB Approval Number: EH17-269
Sponsor:  National Institute on Deafness and Other Communications Disorders
Contact:  Interested patients may contact Duanny Alva, MPH at 847.570.1783, dalva@northshore.org
Open to Enrollment:  Yes
 
The Patient Decision – Making Process after a Diagnosis of Oral Cavity Cancer
Aims: The purpose of this study is to determine patient understanding of oral cancer with regards to treatment 
Diagnosis: Patients that have been diagnosed with oral cancer and have not yet undergone treatment
Principal Investigator: Cheryl Nocon, MD
IRB Approval Number: EH18-179
Sponsor:  NorthShore University HealthSystem
Contact:  Interested patients may contact Duanny Alva, MPH at 847.570.1783, dalva@northshore.org
Open to Enrollment:  Yes